Skip to main content

Table 2 Influence of demographic and clinical data on MTX intolerance

From: Mutations in the MTHFR gene are not associated with Methotrexate intolerance in patients with juvenile idiopathic arthritis

  MTX tolerant MTX intolerant p
Female Gender 74/106 67/90 0. 525
Age 9,67 ± 4,42 10,83 ± 3,89 0. 055
Age at diagnosis 5,53 ± 4,09 5,13 ± 4,04 0. 495
Disease duration 4,14 ± 3,54 5,70 ± 3,78 0. 003*
Duration of MTX treatment 1,83 ± 2,33 2,45 ± 2,32 0. 064
MTX dose/m2 BSA 12,29 ± 2,08 11,63 ± 2,00 0. 026
s.c. dosing 47/106 40/90 1. 000
Folic acid supplementation 103/106 81/90 0. 069
Elevated LFT 18/106 22/90 0. 217
Treatment with TNFA 47/106 33/90 0. 309
Treatment with NSAID 37/106 31/90 1. 000
  1. BSA body surface area, LFT liver function tests, TNFA TNFα antagonist, NSAID non-steroidal anti-inflammatory drug
  2. * significant after Bonferroni correction